GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

Acepodia’s core offering is allogeneic cell‑therapy for cancer — using targeted design and cell‑engineering technologies to develop safe and effective therapeutic cell drugs, aiming to provide patients with a next‑generation, broadly applicable cancer tre